SCHEMBL2198974

SCHEMBL2198974

Cc1ccc(O)cc1-c1cc(-c2ccncc2)nc2[nH]nc(N)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 5/20 0.38
ROCK2 O75116 5/20 0.38
MAP4K4 O95819 5/20 0.38
CLK4 Q9HAZ1 5/20 0.38
CDC7 O00311 4/20 0.38
PIM1 P11309 4/20 0.38
PRKACA P17612 4/20 0.38
CDK2 P24941 4/20 0.38
HIPK2 Q9H2X6 4/20 0.38
IRAK4 Q9NWZ3 4/20 0.38
MKNK2 Q9HBH9 2/20 0.38
CDK7 P50613 1/20 0.38
CDK9 P50750 1/20 0.38
PDPK1 O15530 3/20 0.36
AGPAT2 O15120 1/20 0.36
FYN P06241 1/20 0.35
ILK Q13418 1/20 0.35
JAK2 O60674 1/20 0.34
VCP P55072 1/20 0.34
KIT P10721 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2202555 0.81 PIK3CA (0.41) GSK3BROCK2MAP4K4CLK4CDC7
SCHEMBL2201610 0.79 ROCK2 (0.38) GSK3BROCK2MAP4K4CLK4CDC7
SCHEMBL2207661 0.79 KIT (0.41) GSK3BMAP4K4CDK2MKNK2PDPK1
SCHEMBL2200619 0.79 AGPAT2 (0.35) ROCK2MAP4K4CLK4MKNK2AGPAT2
SCHEMBL2200671 0.76 ACHE (0.41) GSK3BROCK2MAP4K4CLK4CDC7
SCHEMBL13329663 0.76 ACHE (0.52) GSK3BCDC7MKNK2PDPK1AURKA
SCHEMBL2201274 0.74 ACHE (0.45) GSK3BROCK2MAP4K4CLK4CDC7
SCHEMBL2202501 0.72 ACHE (0.47) ROCK2MAP4K4CLK4PIM1PRKACA
SCHEMBL6115704 0.70 BTK (0.56)
SCHEMBL13329255 0.69 MAPT (0.49) GSK3BMKNK2PDPK1JAK2AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1846402-B1 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES BAYER IP GMBH (DE) 2014-02-26 EP disclosed
EP-1846402-B1 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES BAYER IP GMBH (DE) 2014-02-26 EP disclosed
US-7977325-B2 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AG (DE) 2011-07-12 US disclosed
US-7977325-B2 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AG (DE) 2011-07-12 US disclosed
US-7977325-B2 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AG (DE) 2011-07-12 US disclosed
US-20090030010-A1 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents GENESYS CLOUD SERVICES, INC. 2009-01-29 US disclosed
US-20090030010-A1 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents GENESYS CLOUD SERVICES, INC. 2009-01-29 US disclosed
US-20090030010-A1 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents GENESYS CLOUD SERVICES, INC. 2009-01-29 US disclosed
EP-1846402-A1 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES Bayer Schering Pharma Aktiengesellschaft (DE) 2007-10-24 EP disclosed
WO-2006063805-A1 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES BAYER SCHERING PHARMA AKTINGESELLSCHAFT (DE) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030010-A1 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents MAP4K2, ABL1, MAP4K3 GSK3B 510/4885ROCK2 368/4885MAP4K4 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.